UBS Global Biopharma Conference 2026
Logotype for Telix Pharmaceuticals Limited

Telix Pharmaceuticals (TLX) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Telix Pharmaceuticals Limited

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

Commercial base and growth

  • 2026 imaging revenue ~ $1bn; generated >$400m in cash for R&D, infrastructure and supply-chain investment.

  • Illuccix and Gozellix serve 22 countries and hold just over 40% market share; the prostate business grew >25% in 2026.

  • Q3 was flat as planned and FY guidance was reiterated; a strong Q4 exit supported expectations for continued growth, with 5%-7% underlying PSMA market growth.

  • Management expects 25% of PSMA scans to be performed under urology supervision within three years, supported by practice-based pharmacy and scanner infrastructure.

Commercial pipeline and label expansion

  • BYPASS phase III enrollment is complete; data are expected in late Q1 or early Q2 2027, with potential to add nearly 1m U.S. scans and a fast-track, rolling NDA pathway.

  • BYPASS aims to use PET plus MRI to guide biopsy decisions; management cited 1-1.2m U.S. template biopsies annually and 200,000-300,000 men who avoid the current process.

  • Zircaix BLA resubmission is expected before end-2026; approval is currently expected toward the end of H1 2027, following resolution of FDA manufacturing consultations.

  • Pixclara has a broad glioblastoma label, reimbursement begins in January, and uptake has been swift; management sees a few-hundred-million-dollar U.S. opportunity, potentially exceeding $500m with CNS metastases.

ITM transaction and supply strategy

  • The ITM transaction is agreed, with closing targeted before end-2026 subject to conditions; management highlighted the addition of ~800 radiopharma experts.

  • ITM brings global, terabecquerel-scale lutetium supply and Actineer actinium capabilities; management cited 42 mid- or late-stage assets requiring lutetium and emphasized supply security.

  • ITM-11 could advance the therapeutics transition by ~18 months versus the prior late-2028 trajectory; its long shelf life and distribution flexibility support commercial reach.

  • ITM-11 label-expansion readouts in second- and third-line GEP-NET and lung NET are expected in 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Telix Pharmaceuticals